The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma: Results of a phase II study

Cancer

Volumn 104, Issue 5, 2005, Pages 1058-1065

  Arpaci, Fikret ^a,b   Ataergin, Seimin ^a   Ozet, Ahmet ^a   Erler, Kaan ^a   Basbozkurt, Mustafa ^a   Ozcan, Ayhan ^a   Komurcu, Seref ^a   Ozturk, Bekir ^a   Celasun, Bulent ^a   Kilic, Selim ^a   Kuzhan, Okan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Department of Medical Oncology and Bone Marrow Transplantation ^*  (Turkey)

Author keywords

High dose chemotherapy; Limb sparing surgery; Necrosis rate; Nonmetastatic osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG MEGADOSE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR NECROSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NECROSIS; NEOADJUVANT THERAPY; OSTEOSARCOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 23844498805     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21279     Document Type: Article

References (33)

1. Bacci G, Ferrari S, Bertoni F, et al. Long term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027.
2. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
3. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer. 1992; 69:698-708.
4. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
5. Raymond AK, Chawla SP, Carrasco CH, et al. Ostecosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987;4:212-236.
6. Hawkins DS, Felgenhauer J, Park J, et al. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer. 2002;95:1354-1365.
7. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol. 2002;20:2150-2156.
8. Sauerbrey A, Bielack S, Kempf-Bielack B, et al. High-dose chemotherapy and autologous stem cell transplantation as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant. 2001;27:933-937.
9. Patel RS, Papadopolous N, Raymond AK, et al. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer. 2004;101:156-163.
10. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106-120.
11. Enneking WF. Modification of the system for functional evaluation of surgical management of musculoskelatal oncology. New York: Churchill Livingstone, 1987.
12. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14-18.
13. Shimizu T, Saijo N. Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment [in Japanese]. Nippon Rinsho. 2003;61:937-942.
14. Aparicio J, Segura A, Montalar J, et al. Long-term results after combined modality treatment for non-metastatic osteosarcoma. Med Oncol. 1999;16:255-260.
15. Zalupski MM, Rankin C, Ryan JR, et al. Adjuvant therapy of osteosarcoma-A Phase II trial: Southwest Oncology Group study 9139. Cancer. 2004;100:818-825.
16. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol. 2003;25:845-853.
17. Bacci G, Ferrari S, Tienghi A, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neoadjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27:98-104.
18. Wilkins RM, Cullen JW, Odom L, et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol. 2003;10:498-507.
19. Bielack S, Beck J, Deiling G, et al. Neoadjuvant chemotherapy of osteosarcoma. Results of the cooperative studies COSS-80 and COSS-82 after 7 and 5 years [in German]. Klin Padiatr. 1989;201:275-284.
20. Kosen G, Nirenberg A. Neoadjuvant chemotherapy for osteogenic sarcoma: a five year follow-up (T-10) and preliminary report of new studies (T-12). Prog Clin Biol Res. 1985; 201:39-51.
21. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452-2458.
22. Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histologic responders. Eur J Cancer. 2003;39:488-494.
23. Biron P, Rolland F, Thyss A, et al. OSAD 93: a multicentric prospective phase II study of preoperative high-dose Ifosfamide and CDDP in adult patients with non-metastatic osteosarcoma [abstract 9019]. Proc Am Soc Clin Oncol. 2004; 22:14S.
24. Assi H, Le Deley MC, Missenard P. Intensive induction chemotherapy without methothrexate in adult patients with localised osteosareoma: updated results of the Institut Gustave Roussy phase II trial [abstract 9120]. Proc Am Soc Clin Oncol. 2004;9020:819.
25. Michelagnoli MP, Lewis IJ, Gattamaneni HR, Bailey CC, Lashford LS. Ifosfamide/etoposide alternating with high-dose methothrexate: evaluation of chemotherapy regimen for poor risk osteosarcoma. Br J Cancer. 1999;79:1174-1178.
26. Bacci G, Picci P, Ferrari S et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patientes preoperatively treated with high-doses of methothrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227-3238.
27. Ben Arush MW, Stein ME, Kuten A, et al. Postsurgical etoposide-ifosfamide regimen in poor risk nonmetastatic osteogenic sarcoma. Am J Clin Oncol. 1998;21:72-74.
28. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-899.
29. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
30. Bacci G, Ruggieri P, Bertoni F, et al. Local and systemic control of osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience. Oncol Rep. 2000;7:1129-1133.
31. Brosjo O. Surgical procedure and local recurrence in 223 patients treated 1982-1997 according to two osteosarcoma chemotherapy protocols. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl. 1999;285:58-61.
32. Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand. 1998;69:230-236.
33. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol. 2001;19:171-182.